Bio Green Med Solution, Inc. — 2016 Q3 Form 10-Q Summary
Filing identity discrepancy: The supplied filing is for Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc. It reports the quarter and nine months ended September 30, 2016. Confirm that this is the intended filing before relying on the figures below. Amounts are in U.S. dollars; financial statement amounts shown in thousands have been converted to millions where indicated. Share and per-share amounts reflect the company’s one-for-twelve reverse stock split.
Business context and reporting period
Cyclacel is a clinical-stage biopharmaceutical company developing small-molecule medicines, principally for cancer. Its lead program, sapacitabine, was being evaluated in the SEAMLESS Phase 3 study for elderly patients with acute myeloid leukemia (AML). The company had no product revenue from its current drug candidates and depended on grants, research and development tax credits, equity financing, and potential licensing or collaboration arrangements.
Financial performance and liquidity
| Metric | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
|---|---|---|
| Revenue | $0.205 million | $0.566 million |
| Research and development expense | $2.409 million | $7.545 million |
| General and administrative expense | $1.273 million | $4.002 million |
| Operating loss | $3.477 million | $10.981 million |
| Net loss | $2.946 million | $8.952 million |
| Net loss attributable to common shareholders | $2.996 million | $9.102 million |
| Basic and diluted net loss per share | $0.86 | $2.89 |
| Net cash used in operating activities | Not presented separately for the quarter | $7.136 million |
At September 30, cash and cash equivalents were $18.029 million, total current assets were $22.579 million, and total current liabilities were $5.570 million. Total assets were $22.652 million and total liabilities were $5.711 million. The balance sheet reports no conventional borrowings; material obligations include operating leases and potential license milestones. Stockholders’ equity was $16.941 million.
Cash decreased by $2.411 million from year-end 2015. Financing activities provided $5.091 million net cash for the nine months, including $5.241 million of net common-stock proceeds and $0.150 million in preferred dividends paid. The filing also reports $1.518 million receivable for shares issued before quarter-end and settled in October.
Changes versus the prior comparable period
- Third-quarter revenue fell 71% to $0.205 million from $0.715 million in 2015, as grant revenue declined and the prior-year $0.253 million ManRos collaboration revenue did not recur.
- Third-quarter research and development expense declined 17% to $2.409 million, primarily due to lower SEAMLESS trial costs and reduced grant-funded program spending. General and administrative expense increased 6% to $1.273 million.
- Third-quarter net loss attributable to common shareholders increased to $2.996 million from $2.759 million; loss per share decreased to $0.86 from $0.95, with a higher weighted-average share count in 2016.
- For the nine months, revenue declined 63% to $0.566 million. Research and development expense declined 23% to $7.545 million, while general and administrative expense was essentially unchanged.
- Nine-month net loss attributable to common shareholders improved to $9.102 million from $11.118 million. Other income improved, largely reflecting foreign-exchange gains in 2016 versus losses in 2015.
- Cash declined from $20.440 million at December 31, 2015 to $18.029 million at September 30, 2016. Common shares outstanding increased from 2,965,208 to 4,251,229 during that period.
Outlook, management commentary, risks and unusual items
- SEAMLESS: The required 424 events had been reached, and data cleaning and validation were underway before database lock and independent statistical analysis. Management said final data and any regulatory submission decision could take several months. The December 2014 interim review had crossed the prespecified futility boundary; the DSMB said statistically significant survival improvement appeared unlikely based on interim data, but identified no safety concern and recommended continued follow-up.
- Funding: Management expected existing resources to fund planned operations into the second half of 2018, but said substantial additional capital would be needed for sapacitabine development and the CDK inhibitor program. If financing is unavailable, the company may reduce or delay programs, pursue collaborations, or limit or cease operations.
- Spending and revenue outlook: Management expected 2016 R&D spending to decline versus 2015 as SEAMLESS follow-up and site closures reduced costs. Approximately $0.3 million of CYC140 grant revenue was expected through November 2016. Future grant, collaboration, and licensing revenue was uncertain.
- Equity financing: Under its FBR at-the-market agreement, the company reported approximately $6.7 million in net proceeds from shares sold through September 30 and approximately $1.2 million of additional shares available under the cited prospectus supplement. These sales dilute existing shareholders. Some proceeds from shares issued before quarter-end were collected in October.
- Foreign exchange and Brexit: Currency movements affected reported results; management cited Brexit-related market and exchange-rate volatility and warned that currency changes could adversely affect results.
- Preferred stock: 335,273 preferred shares remained outstanding, with a $4.0 million aggregate liquidation preference and cumulative 6% dividends. A $0.15-per-share quarterly dividend was declared in September and scheduled for payment November 1, 2016.
- Other risks and contingencies: Drug approval and commercial success are uncertain; the Phase 3 futility finding, financing needs, dilution, dependence on third parties, intellectual-property challenges, competition, and regulatory requirements are significant risks. Contractual operating lease obligations totaled $3.045 million. The filing reported no legal proceedings and no off-balance-sheet arrangements. Management said disclosure controls were effective as of September 30, 2016.
Important facts for investors to verify
- Whether Cyclacel Pharmaceuticals, Inc. is the intended company, given the mismatch with the requested Bio Green Med Solution, Inc.
- The final SEAMLESS study results, timing of database lock and analysis, and whether regulators consider the data suitable for a filing.
- Whether the stated cash runway remains achievable, considering operating cash use, future trial and regulatory costs, and additional financing needs.
- ATM share sales, October settlement of the quarter-end receivable, remaining offering capacity, and resulting dilution.
- Preferred dividend obligations and liquidation preference, as well as ongoing Nasdaq listing compliance and share-price risks.